Hereditary angioedema: lanadelumab cuts attack rates

Subcutaneous lanadelumab for 26 weeks reduced the rate of attacks in patients with hereditary angioedema type I or II.
Subcutaneous lanadelumab for 26 weeks reduced the rate of attacks in patients with hereditary angioedema type I or II.